Dental and Medical Problems

Dent Med Probl
Index Copernicus (ICV 2021) – 132.50
MEiN – 70 pts
CiteScore (2021) – 2.0
JCI (2021) – 0.5
Average rejection rate (2022) – 79.69%
ISSN 1644-387X (print)
ISSN 2300-9020 (online)
Periodicity – quarterly

Download PDF

Dental and Medical Problems

2014, vol. 51, nr 3, July-September, p. 402–409

Publication type: clinical case

Language: English

Creative Commons BY-NC-ND 3.0 Open Access

PerioFilm Preparation in the Complicated Endodontic Retreatment of a Tooth with Apical Resorption During Orthodontic Therapy

Ocena zastosowania preparatu PerioFilm w powikłanym leczeniu endodontycznym w trakcie leczenia ortodontycznego zęba z zaawansowaną resorpcją wierzchołkową

Katarzyna Banaszek1,A,B,D,E,F, Monika Łysakowska2,B,C,D,E, Jerzy Sokołowski1,E

1 Department of General Dentistry, Chair of Restorative Dentistry, Medical University of Lodz, Lodz, Poland

2 Department of Medical and Sanitary Microbiology, Medical University of Lodz, Lodz, Poland


The article presents the use of the PerioFilm adhesive dressing containing antibiotic piperacillin in the complicated endodontic retreatment of tooth 11 with severe apical resorption and alveolar bone loss in a young patient. Ongoing orthodontic therapy could lead to the loss of the tooth. Due to a suspicion of Enterococcus faecalis infection of the root canal system of tooth 11, additional microbiological examinations of Enterococcus faecalis strains sensitivity to piperacillin were performed. The piperacillin contained in the preparation was compared in vitro to other antibiotics and chemotherapeutics used in the treatment of Enterococcus faecalis infections. The results of the piperacillin action suggest that this antibiotic inhibits the growth of Enterococcus faecalis strains including those which are resistant to the other antibiotics and chemotherapeutics studied. The treatment caused inhibition of the inflammatory process and partial regeneration of the periapical bone tissues. Thus, it seems to be a valuable alternative and effective agent in the treatment of post-endodontic complications caused by Enterococcus faecalis infections.


W pracy przedstawiono przypadek zastosowania preparatu PerioFilm w powikłanym powtarzanym wcześniej leczeniu endodontycznym w trakcie leczenia ortodontycznego zęba 11 z zaawansowaną resorpcją wierzchołkową. Substancją czynną w tym preparacie jest piperacylina, a nośnikiem mieszanka biodegradowalnych żywic. Uzyskano wstępnie dobre wyniki powtórnego leczenia endodontycznego tym preparatem. Ze względu na podejrzenie zakażenia o etiologii Enterococcus faecalis dotyczącego systemu kanałowego zęba 11 zdecydowano się przeprowadzić dodatkowe badania mikrobiologiczne wrażliwości szczepów ziarenkowca Enterococcus faecalis na pieperacylinę i inne chemioterapeutyki. Porównano in vitro działanie piperacyliny wchodzącej w skład preparatu do innych antybiotyków i chemioterapeutyków stosowanych w terapii zakażeń Enterococcus faecalis. Wyniki działania piperacyliny sugerują, że ma działanie hamujące wzrost szczepów Enterococcus faecalis, w tym tych, które są oporne na wiele badanych antybiotyków i chemioterapeutyków, zatem stanowi cenną alternatywę w leczeniu zakażeń w obrębie jamy ustnej powodowanych przez te drobnoustroje. Preparat PerioFilm wydaje się skuteczny w leczeniu powikłań powstałych w leczeniu zespołu endo-perio.

Key words

endo-perio syndrome, antibiotic, PerioFilm, endodontic retreatment, Enterococcus faecalis

Słowa kluczowe

zespół endo-perio, PerioFilm, antybiotyk, leczenie endodontyczne, Enterococcus faecalis

References (31)

  1. Tronstad L.: Root resorption – etiology, terminology and clinical manifestations. Endod. Dent. Traumatol. 1988, 4, 241–252.
  2. L evander E., Malmgren O., Stenback K.: Apical root resorption during orthodontic treatment of patients with multipla aplasia: a study of maxillary incisors. Eur. J. Orthod. 1998, 20, 427–434.
  3. Zehnder M., Guggenheim B.: The mysterious appearance of enterococci in filled root canals. Int. Endod. J. 2009, 42, 277–287.
  4. S iqueira J.E. Jr.: Aetiology of root canal treatment failure: why well-treated teeth can fail. Int. Endod. J. 2001, 34, 1–10.
  5. Wu M.K., Dummer P.M., Wesselink P.R.: Consequences of and strategies to deal with residual post-treatment root canal infection. Int. Endod. J. 2006, 39, 343–356.
  6. Pinheiro E.T., Gomes B.P., Ferraz C.C., Sousa E.L., Teixeira F.B., Souza-Filho F.J.: Microorganisms from canals of root-filled teeth with periapical lesions. Int. Endod. J. 2003, 36, 1–11.
  7. Molander A., Reit C., Dahlén G., Kvist T.: Microbiological status of root-filled teeth with apical periodontitis. Int. Endod. J. 1998, 31, 1–7.
  8. Gomes B., Pinheiro E.T., Gadê-Neto C.R., Sousa E.L., Ferraz C.C., Zaia A.A., Teixeira F.B., Souza-Filho F.J.: Microbiological examination of infected dental root canals. Oral. Microbiol. Immunol. 2004, 19, 71–76.
  9. Zoletti G.O., Pereira E.M., Schuenck R.P., Teixeira L.M., Siqueira J.F. Jr, dos Santos K.R.: Characterization of virulence factors and clonal diversity of Enterococcus faecalis isolates from treated dental root canals. Res. Microbiol. 2011, 162, 151–158.
  10. Cetinkaya Y., Falk P.S., Mayhall C.G.: Vancomycin-resistant enterococci. Clin. Microbiol. Rev. 2000, 13, 687–707.
  11. L evander E., Bajka R., Malmgren O.: Early radiographic diagnosis of apical root resoption during orthodontic treatment: a study of maxillary incisors. Eur. J. Orthod. 1998, 20, 57–63.
  12. L evander E., Malmgren O.: Long-term follow-up of maxillary incisors with severe apical root resorption. Eur. J. Orthod. 2000, 22, 85–92.
  13. Kariyama R., Mitsuhata R., Chow J.W., Clewell D.B., Kumon H.: Simple and reliable multiplex PCR assay for surveillance isolates of vancomycin-resistant enterococci. J. Clin. Microbiol. 2000, 38, 3092–3095.
  14. Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement.CLSI document M100-S16 [ISBN 1-56238-588-7]. Clinical and Laboratory Standards Institute, Pennsylvania 19087–1898 USA, 2006.
  15. Hryniewicz W., Sulikowska A., Szczypa K., Gniadkowski M., Skoczynska A.: Recommendations for susceptibility testing to antimicrobial agents of selected bacterial species. Post. Mikrobiol. 2005, 44, 175–192 [in Polish].
  16. Visconti P.C., Capuano A., Parrini S.: Local antibiotic therapy with sodium piperacillin (a slow-release preparation). Dent. Cadmos. 2003, 4, 73–82.
  17. Banaszek K., Klimek L.: Initial evaluation of PerioFilm biodegradation – a SEM study. Twój Prz. Stomatol. 2011, 1–2, 54–57 [in Polish].
  18. N eely A.N., Maley M.P.: Survival of enterococci and staphylococci on hospital fabrics and plastic. J. Clin. Microbiol. 2000, 38, 724–726.
  19. S un J., Song X., Kristiansen B.E., Kjaereng A., Willems R.J., Eriksen H.M., Sundsfjord A., Sollid J.E.: Occurrence, population structure, and antimicrobial resistance of enterococci in marginal and apical periodontitis. J. Clin. Microbiol. 2009, 47, 2218–2225.
  20. Rams T.E., Feik D., Young V., Hammond B.F., Slots J.: Enterococci in human periodontitis. Oral. Microbiol. Immunol. 1992, 7, 249–252.
  21. Piekarska K., Kochman M., Lawrynowicz-Paciorek M.: Characteristic of clinical fluoroquinolone resistant isolates of E. faecalis. Med. Dosw. Mikrobiol. 2005, 57, 345–453 [in Polish].
  22. Hancock H.H. 3rd, Sigurdsson A., Trope M., Moiseiwitsch J.: Bacteria isolated after unsuccessful endodontic treatment in a N orth American population. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2001, 91, 579–586.
  23. Weber A., Huber W., Kamereck K., Winkle P., Voland P., Weidenbach H., Schmid R.M., Prinz C.: In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis. World J. Gastroenterol. 2008, 14, 174–178.
  24. Zhanel G.G., DeCorby M., Laing N., Weshnoweski B., Vashisht R., Tailor F., Nichol K.A., Wierzbowski A., Baudry P.J., Karlowsky J.A., Lagacé-Wiens P., Walkty A., McCracken M., Mulvey M.R., Johnson J.: Canadian Antimicrobial Resistance Alliance (CARA), Hoban D.J.: Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005–2006. Antimicrob. Agents Chemother. 2008, 52, 1430–1437.
  25. Claesson C., Hällgren A., Nilsson M., Svensson E., Hanberger H., Nilsson L.E., Scope Study Group.: Susceptibility of staphylococci and enterococci to antimicrobial agents at different ward levels in four northern European countries. Scand. J. I nfect. Dis. 2007, 39, 1002–1012.
  26. Hanberger H., Erlandsson M., Burman L.G., Cars O., Gill H., Lindgren S., Nilsson L.E., Olsson-Liljequist B., Walther S. and the ICU-Strama Study Group: High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand. J. I nfect. Dis. 2004, 36, 24–30.
  27. Claesson C., Nilsson L.E., Kronvall G., Walder M., Sörberg M.: Antimicrobial activity of tigecycline and comparative agents against clinical isolates of staphylococci and enterococci from ICUs and general hospital wards at three Swedish university hospitals. Scand. J. I nfect. Dis. 2009, 41, 171–181.
  28. Milatovic D., Schmitz F.J., Verhoef J., Fluit A.C.: Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 2003, 47, 400–404.
  29. Biedenbach D.J., Bell J.M., Sader H.S., Fritsche T.R., Jones R.N.,Turnidge J.D.: Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SEN TRY program report (2003–2004). Int. J. A ntimicrob. Agents. 2007, 30, 143–149.
  30. Friedman S.: Considerations and concepts of case selection in the management of post-treatment endodontic disease (treatment failure). Endod. Topics. 2002, 1, 54–78.
  31. Wada M., Takase T., Nakanuma K., Arisue K., Nagahama F., Yamazaki M.: Clinical study of refractory apical periodontitis treated by apicectomy. Part 1. Root canal morphology of resected apex. Int. Endod. J. 1998, 31, 53–56.